Larimar Therapeutics Inc (fra:ZA71) Share Price

Company Profile

Business description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Contact
Three Bala Plaza East
Suite 506
Bala CynwydPA19004
USA
T: +1 844 511-9056
https://www.larimartx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
71

Recommended

Headwinds in listed energy stocks likely to have passed

Esther Holloway | 30 March 2026

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.

Franco Granda | 30 March 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Tyger Fitzpatrick | 30 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,747.40	75.00	0.86%
CAC 40	7,772.45	70.50	0.92%
DAX 40	22,562.88	262.13	1.18%
Dow JONES (US)	45,216.14	49.50	0.11%
FTSE 100	10,127.96	160.61	1.61%
HKSE	24,657.41	93.38	-0.38%
NASDAQ	20,794.64	153.72	-0.73%
Nikkei 225	51,820.30	65.55	-0.13%
NZX 50 Index	12,866.42	117.50	0.92%
S&P 500	6,343.72	25.13	-0.39%
S&P/ASX 200	8,546.50	69.30	0.82%
SSE Composite Index	3,910.01	13.27	-0.34%